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Background: Current point-of-care tests (POCT) for syphilis, based on the detection of Treponema pallidum
(TP) total antibodies, have limited capacity in distinguishing between active and past/treated syphilis. We
report the development and early evaluation of a new prototype POCT based on the detection of TP-IgA anti-
bodies, a novel biomarker for active syphilis.
Methods: The TP-IgA POCT (index test) was developed in response to the World Health Organisation (WHO)
target product profile (TPP) for a POCT for confirmatory syphilis testing. Two sub-studies were conducted
consecutively using 458 pre-characterised stored plasma samples in China (sub-study one, addressing the
criteria for the WHO TPP), and 503 venous blood samples collected from pregnant/postpartum women in
South Africa (sub-study two, addressing potential clinical utility). Performance of the index test was assessed
against standard laboratory-based serology using a combination of treponemal (TPHA) and non-treponemal
(rapid plasma reagin [RPR]) tests.
Findings: In sub-study one, the index test demonstrated 96¢1% (95%CI=91¢7%-98¢5%) sensitivity and 84¢7%
(95%CI=80¢1588¢6%) specificity for identification of active syphilis (TPHA positive, RPR positive). It correctly
identified 71% (107/150) samples of past-treated syphilis (TPHA positive, RPR negative). In sub-study two,
the index test achieved 100% (95%CI=59%-100%) sensitivity for active syphilis and correctly identified all nine
women with past syphilis.
Interpretation: The TP-IgA POCT has met the WHO TPP for a POCT for diagnosis of active syphilis and demon-
strated its potential utility in a clinical setting. Future studies are warranted to evaluate field performance of
the final manufactured test.
Funding: Saving Lives at Birth: Grand Challenge for Development, Thrasher Research Fund, and the Victorian
Government Operational Infrastructure Scheme.
© 2020 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license.
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Research in context
Evidence before this study
Maternal and congenital syphilis has re-emerged as a global
health challenge. In resource-constrained settings, limited
availability and lack of access to confirmatory testing of active
infection constrain efforts to prevent congenital syphilis. We
searched PubMed to identify peer-reviewed articles reporting
performance of POCTs that can be used for confirmatory testing
of active syphilis. We found that the Dual Path Platform (DPP)
Screen & Confirm Assay is the only POCT with field evaluation
data but has limited capacity in distinguishing between active
and past/treated syphilis.
Added value of this study
This is the first study to assess diagnostic performance and clin-
ical utility of a newly developed TP-IgA POCT for confirmatory
syphilis testing. Results of this study provide empirical evi-
dence showing that when used in combination with standard
TP screening methods, the new confirmatory test has capacity
to identify past syphilis whilst maintaining a high sensitivity
for active syphilis infections compared to other POCTs on the
market. This finding represents a significant development in
the POC diagnostic landscape for syphilis, supporting the global
effort in prevention of mother to child transmission and elimi-
nation of congenital syphilis in settings where laboratory
capacity is limited.
Implication of all the available evidence
Data from the WHO global sexually transmitted infection sur-
veillance suggest that the global targets for screening and treat-
ment of syphilis among pregnant women are not being met
with only 18/194 (9%) of countries have achieved at least 95%
of pregnant women screened for syphilis and 95% who tested
positive receiving treatment. Low and middle-income countries
(LMICs) with limited resources for health face the greatest chal-
lenges. Current, commonly used rapid POCTs for syphilis have
limited capacity in distinguishing between active and past
infections, leading to over-treatment and further strains on
health care resources. The availability of the TP-IgA POCT as a
confirmatory test for women initially reactive with a screening
POCT will provide more options for LMICs to enhance effective
and efficient use of limited health system resources for screen-
ing, diagnosis and treatment of active syphilis among pregnant
women.
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Syphilis is a curable sexually transmitted infection (STI), caused by
the bacterium Treponema pallidum (TP). Globally, an estimated six
million new cases of syphilis are diagnosed annually, most of the
infections occur in low and middle-income countries (LMICs) and
congenital syphilis is not uncommon [1]. An analysis on trend over
time of syphilis in 132 countries showed that between 2012 and
2016, the prevalence of active syphilis in women of reproductive age
(15 to 49 years) had increased in 78 countries, of which 10 (13%)
were substantive (10% proportionally, 0.10% percentage-point
absolute difference and non-overlapping 95% confidence intervals in
2012 and 2016) whilst among 54 countries with observed decreased
prevalence only five (9%) countries experienced a substantive
decrease [2].Treatment of syphilis is relatively simple, effective and inexpen-
sive with one dose of Benzathine penicillin [3]. However, diagnosis
of active syphilis, particularly in LMICs, is often challenging due to
the persistence of IgG antibodies to TP after prior treated syphilis
infections, which necessitates a combination of treponemal (e.g.
TPHA, TPPA) and non-treponemal (e.g. RPR) tests to distinguish
active from past treated infections. Availability and introduction of
point-of-care tests (POCTs) has increased access to testing for syphi-
lis; however, current POCTs for serological diagnosis of syphilis only
detect IgG or both IgG and IgM antibodies specific to TP. It is known
that serological tests based on IgG cannot distinguish between
active and treated infections, and IgM tests can be highly sensitive
in symptomatic patients but have suboptimal sensitivity in asymp-
tomatic cases [4].
The Dual Path Platform (DPP) Syphilis Screen & Confirm test
(Chembio Diagnositcs, Medford, NY, USA) is the first commercially
available rapid POCT that gives both treponemal and non-treponemal
results that assist in distinguishing between current and past infec-
tion [5]. However, marked variation in diagnostic performance of the
test has been reported particularly in the sensitivity and specificity of
the non-treponemal component [5,6]. A laboratory evaluation in Aus-
tralia [7] reported that 49¢8% (105/211) presumptive past treated
serum samples were misclassified as active syphilis by the DPP test,
whereas a field evaluation among pregnant women in Burkina Faso
[8] showed 48¢4% (44/91) women with active syphilis would be undi-
agnosed had the DPP test been used. The difference in test perfor-
mance can be partly explained by the lot-to-lot variation as a
laboratory study in the United States[9] showed a significant differ-
ence in the sensitivity for the non-treponemal component of the DPP
in two different lots studied - 65¢3% (95%CI: 60¢569¢8) and 80¢9%
(95%CI: 72¢687¢2) respectively.
Given that the re-emergence of a syphilis epidemic among preg-
nant women and key populations is a global health concern [10],
innovative assays using a biomarker that can accurately distinguish
between past, treated and active infection at the point-of-care (POC)
are need. Access to such an assay will improve diagnosis and facilitate
appropriate treatment in a timely manner [11]. To promote research
and development of reliable, low-cost POCTs for syphilis, the WHO
developed a Target Product Profile (TPP) identifying minimum and
preferred assay performance for screening and confirmation of active
syphilis (and other STIs) [12]. The TPP specifies a minimum clinical
sensitivity of >80% for patients with high-titre RPR (8) and specific-
ity of >80%, with optimal performance of >90% and >95%, respec-
tively, for screening and confirmation of syphilis infection. The WHO
TPP also highlighted the need for identification of new markers for
acute syphilis infection [12]. With these needs in mind, researchers
at the Burnet Institute developed a novel POCT for diagnosis of active
syphilis infection based on detection of TP-specific IgA antibodies.
Whilst TP-IgG/IgM antibodies have shown some promise as a bio-
marker for acute syphilis infection, TP-IgA has not been systemati-
cally evaluated before. Our laboratory experiments using enzyme-
linked immunosorbent assays (ELISAs) with confirmed active syphilis
and past syphilis samples revealed two observations that have led to
development of a more sensitive and specific POCT. Firstly, TP-spe-
cific IgA had higher reactivity rates than IgM in active syphilis sam-
ples. Secondly, inclusion of a novel TP antigen (TP0453) [13] along
with the conventional antigens used in most POCTs further boosted
IgA sensitivity, reaching the WHO TPP for confirmation of active
syphilis. These reagents were subsequently incorporated into the TP-
IgA POCT. During evaluation of early test prototypes using 79 refer-
ence plasma samples from the National Serology Reference Labora-
tory (Melbourne, Australia) the TP-IgA POCT achieved 91¢2%
sensitivity (31/34) for target active syphilis samples, 76% specificity
(19/25) for samples of past-treated syphilis, and 95% (19/20) specific-
ity for healthy control (no syphilis) samples, potentially meeting the
WHO TPP (unpublished data).
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prototype TP-IgA POCT for detection and differentiation of active
syphilis, firstly in a reference laboratory setting in China to determine
test performance compared with the WHO TPP, and secondly in an
antenatal clinical setting in South Africa to address potential clinical
utility of the test.2. Methods
2.1. Test under evaluation
The TP-IgA POCT is a lateral flow, in-house manufactured immu-
nochromatographic test designed to detect TP-specific IgA class anti-
bodies. The test incorporates a mixture of TP chimeric Recombinant
antigen (TpN15, TpN17, TpN47; Fapon, China) and Tp0453 antigen
(Meridian Life Sciences, USA). It uses 5ml of specimen (whole blood,
plasma or serum), which flows through a membrane where TP-spe-
cific IgA antibodies from the specimen binds with treponemal anti-
gens immobilised on the membrane as a line in the test area marked
“Test line”. Other IgA antibodies (along with other sample constitu-
ents) continue migrating along the membrane and immunoglobulins
of IgG, IgM and IgA class (if present) bind with immobilised protein L
in the control line area marked “Control line”. Anti-human IgA colloi-
dal gold is rehydrated and migrates past the treponemal-specific IgA
bound to the antigens immobilised in the test line area, leading to
the formation of a pink to purple line which confirms a positive test
result. The absence of this line indicates a negative result. Unbound
anti-human IgA gold continues to migrate to the IgA bound to the
control line area, forming a deep pink to purple line. Absence of the
control line indicates an invalid result (if the test has not been per-
formed properly) or the presence of IgA deficiency in the patient. The
total testing procedure should take 30 min. (Fig. 1)Fig. 1. Testing procedure and res2.2. Study design
Two sub-studies were conducted consecutively at the National
Centre for STD Control in China (NCSC) and the Rahima Moosa
Mother and Child hospital (RMMCH) in South Africa to address the
stated objectives. The NCSC is part of an international network of
clinical and laboratory-based evaluations of sexually transmitted
infection tests. The Centre had experience in laboratory evaluations
and development of recommendations for use of several approved
rapid diagnostic test for syphilis in China and other countries. The
RMMCH is an academic, regional hospital affiliated with the Univer-
sity of Witwatersrand. In 2018, there were an average of 1075 babies
born per month, with a perinatal mortality rate of 28.9/1000 births.2.2.1. Sub-study 1 - A retrospective laboratory evaluation of diagnostic
accuracy using stored plasma samples in China
Specimen collection: Between June-December 2017, pre-character-
ised stored plasma samples were retrieved from the NCSC laboratory
in Nanjing, China. The samples were selected on the basis of trepone-
mal (TPHA) and non-treponemal (RPR) reactivity for diagnosis of
active syphilis as specified in the WHO TPP. Three sample types were
selected: (i) active syphilis (TPHA positive, RPR 8); (ii) past treated
(TPHA positive, RPR negative); and (iii) no syphilis (TPHA negative,
RPR negative). We obtained ethics approval from the Alfred Hospital
ethics committee in Melbourne (AHEC #220/15) and the Institute of
Dermatology, Chinese Academy of Medical Science (#2016-016).
Reference tests: Selected samples stored at 80 °C were thawed
and underwent confirmatory testing with TPHA and RPR laboratory-
based reference tests following the manufacturer’s instructions to
confirm pre-characterized syphilis status. Discordant results were
retested and samples that remained discordant upon retesting were
excluded and additional samples were requested. Only samples withult window of TP-IgA POCT.
Table 1
Comparison of the TP-IgA POCT with RPR reference test results using pre-character-
ised stored plasma samples in China (N = 454).
TP-IgA RPR reference Analytical Performance% (95%CI)
RPR+ 8 Negative Total
Positive 147 46 193 Sensitivity: 96¢1% (91¢7%98¢5%)
Specificity: 84¢7% (80¢1%88¢6%)
Positive Predictive Value (PPV):
76¢2% (69¢5%82%)
Negative Predictive Value (NPV):
97¢7% (95¢1%99¢2%)
Negative 6 255 261
Total 153 301 454*
* Four indeterminate IgA test results excluded from analysis.
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treponemal components were included in the final sample panel
used for the study.
Testing procedure: After confirmatory testing, each sample of the
final sample panel was tested with three different syphilis POCTs: the
TP-IgA POCT (index test), and two syphilis total antibody tests -
the Alere DetermineTM Syphilis TP test (Abbott Diagnostics, UK) and
the Visitect Syphilis test (Omega Diagnostics, UK). The two latter
tests were selected because these were among the most commonly
used rapid POCT for syphilis with good diagnostic performance[14]
and we could not obtain the DPP Syphilis Screen & Confirm test for
this study. All tests were performed by laboratory technicians follow-
ing manufacturer’s instructions; results were read and recorded inde-
pendently of each other.
2.2.2. Sub-study 2  a prospective evaluation of potential clinical utility
using fresh venous blood samples in South Africa
Specimen collection: Between June-December 2018, venous blood
samples were consecutively collected from consenting pregnant or
peripartum women (within two weeks of miscarriage, termination of
pregnancy or childbirth), aged 18 years or older, attending obstetric
and gynaecology department at the RMMCH in Johannesburg, South
Africa. Each participant provided 3 ml venous blood collected in
EDTA tubes for standard syphilis serology (reference) tests and the
index test performed in duplicate by two independent test operators.
Ethics approval was obtained from AHEC (#556/17) and the Human
Research Ethics Committee of the University of Witwatersrand in
South Africa (#R14/49). All participants provided signed informed
consent.
Reference tests: A combination of a treponemal test (TPHA) and a
non-treponemal test (RPR) was used as standard laboratory-based
reference testing for diagnosis of active syphilis infection. For the
treponemal component, the ADVIA Centaur Syphilis assay (Siemens
Healthcare Diagnostics, Tarrytown, NY, USA) was used and for the
non-treponemal component, we used the RPR (Omega Diagnostics,
UK) test. As per standard of care at the study site, a woman who had
reactive results for both TPHA and RPR tests (any titre) was defined
as having active syphilis; a reactive TPHA and non-reactive RPR indi-
cate past/treated syphilis; a non-reactive TPHA and a reactive RPR is
biologically false positive; and non-reactive results to both tests is no
syphilis.
Testing procedure: All blood specimens were processed within
24 h of venepuncture by standard reference and the TP-IgA POCT
assays. The index tests were performed in duplicate by two indepen-
dent trained laboratory technicians at the RMMCH’s research labora-
tory. Results of the index test were obtained and recorded in a
blinded fashion, independent from each other and independent of
the reference tests, which were performed at an offsite laboratory.
2.3. Statistical analysis
For sub-study 1, we used a purposively selected quota-sample of
458 specimens (154 active syphilis, 153 past-treated syphilis and 151
healthy control). This sample size would be adequate to estimate
diagnostic accuracy of the TP-IgA POCT, with 95% confidence level, at
the precision of estimates of 5% and 7% and expected sensitivity and
specificity of 90% and 80%, respectively [15]. For sub-study 2, we
aimed to test diagnostic performance of the TP-IgA POCT in identify-
ing active syphilis using pre-determined values of 96% sensitivity and
85% specificity, based on the results of sub-study 1. We calculated
that a sample size of 500 would provide 99% confidence with 90%
power to detect a difference of 4% from the presumptive value of 96%
for sensitivity and, 95% confidence with 80% power to detect a differ-
ence of 5% from the presumptive value of 85% for specificity [15].
Diagnostic performance of the TP-IgA POCT was assessed by cal-
culating sensitivity, specificity, positive predictive value (PPV) andnegative predictive value (NPV) against standard syphilis serology
tests. Specifically, to assess the performance of the index test as a
non-treponemal confirmatory test for active syphilis, we compared
TP-IgA positivity identified by naked eye with results of RPR. To
ascertain the test capacity in distinguishing between active and past
syphilis, we compared results of the index test to that of standard ref-
erence tests using a combination of treponemal (TPHA) and non-
treponemal (RPR) tests. Performance of the TP-IgA test was also com-
pared to that of the DetermineTM and Visitect syphilis POCTs using
pre-characterised plasma samples (sub-study 1 only). Agreement
between duplicate index tests was assessed using kappa statistics
(sub-study 2 only). Numbers of invalid (no control line) and/or inde-
terminate test results (test operator cannot determine whether or
not a test line was present in the test window) were reported. All
data analysis was performed with Stata version 15¢0.2.4. Role of funding source
The funders of the study had no role in study design, data collec-
tion, data analysis, data interpretation, or writing of the manuscript.
The corresponding author had full access to all the data in the study
and had final responsibility for the decision to submit for publication.3. Results
3.1. Sub-study 1: Diagnostic accuracy study
After confirmatory testing, the final panel consisted of 154 active
syphilis (TPHA positive, RPR 8), 153 past-treated syphilis (TPHA
positive, RPR negative) and 151 no syphilis (TPHA and RPR negative)
samples (Table S1-Suplementary file). These samples came from an
age range of 2 to 81 years (median: 37, IQR: 15, 70); 47% female and
53% male.
Tables 1 and 2 depict the overall results of the TP-IgA POCT using
pre-characterised plasma samples following the WHO TPP categori-
sation [12]. Among 458 samples tested, four returned indeterminate
TP-IgA test results, of which, three samples were characterised as
past-treated (TPHA+/RPR-) and one was active syphilis (TPHA+/RPR
+8) (Table S1). With the remaining 454 samples, when compared to
RPR, the TP-IgA test demonstrated 96¢1% (95%CI=91¢7%98¢5%) sensi-
tivity and 84¢7% (95%CI=80¢188¢6%) specificity for identification of
active syphilis infection (Table 1). Using a combination of TPHA and
RPR as reference, 71% (107/150) of past syphilis samples (TPHA
+/RPR-) returned a negative result with the TP-IgA whereas, as
expected, 92% (133/145) and 100% (153/153) of these samples were
reactive with the Visitect and DetermineTM POCTs, respectively
(Table 2). All 154 active syphilis samples returned reactive results
when tested with Visitect and DetermineTM POCTs. Three syphilis
negative samples that were reactive with TP-IgA were non-reactive
with the two screening tests (Table S1).
Table 2
Performance of the TP-IgA POCT and two other POCTs in identifying active syphilis and distinguishing between active and
past, treated syphilis using pre-characterised stored plasma samples in China (N = 454).
Assays/Reference Active syphilis TPHA+/RPR+ 8 Past/treated TPHA+/RPR- No syphilis TPHA-/RPR- Total
TP-IgA
Positive 147 43 3 193
Negative 6 107 148 261
Total 153* 150* 151 454
DetermineTM Syphilis
Positive 154 153 1 308
Negative 0 0 149 149
Total 154 153 150* 457
Visitect Syphilis
Positive 154 133 4 291
Negative 0 12 145 157
Total 154 145* 149* 448
* Four (IgA), one (DetermineTM) and ten (Visitect) indeterminate rapid test results excluded from analysis.
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Using fresh venous blood samples from prospectively recruited
pregnant/postpartum women in South Africa (N = 503), the TP-IgA
POCT detected all seven RPR positive samples (four RPR 8 and three
RPR<8) but also a small number of samples (3/503 or 0¢6%) that were
negative for RPR (Table 3).
Combining total antibody (TPHA) and RPR testing (Table 4), 5/503
(1%) subjects were diagnosed with active syphilis using the reference
tests (TPHA+, RPR+). The TP-IgA test correctly identified 100% sam-
ples with active syphilis (5/5) and 99% (484/487) samples with no
syphilis infection, and importantly was able to discriminate 9/9 past-
treated syphilis cases (TPHA+, RPR-). The TP-IgA test detected 3/503
samples (0¢6%) that were negative by reference tests and an addi-
tional two samples that were deemed biological false positives
(TPHA-/RPR+) (Flowchart  Supplementary file).
The duplicate TP-IgA tests performed by separate operators deliv-
ered nearly identical results (99¢8% agreement, kappa=0¢95,
p<0.0001) with only one discordant result for which the reference
tests were negative (TPHA-/RPR-) (Table S2  Supplementary file).Table 3
Comparison of the TP-IgA POCT with RPR reference test results using fresh
venous blood samples from pregnant/postpartum women in South Africa
(N = 503).
TP-IgA RPR reference Analytical Performance% (95%CI)
Positive Negative
8 <8 Sensitivity: 100% (59%100%)
Specificity: 99¢4% (98¢2%99¢9%)
PPV: 70% (34¢8%93¢3%)
NPV: 100% (99¢3%100%)
Positive 4* 3* 3 10
Negative 0 0 493 493
4 3 496 503
* Four samples with RPR titre 8 (one 1:8 & three 1:32); three samples with
RPR titre <8 (two 1:1 & one 1:2).
Table 4
Performance of the TP-IgA POCT in identifying active syphilis and disting
dard laboratory reference testing (TPHA/RPR) using fresh venous blo
(N = 503).
TP-IgA/Reference TPHA+/RPR+ TPH
RPR8 RPR<8
Active, high titre Active, low titre Past/ tre
Positive 4 1 0
Negative 0 0 9
Total 4 1 94. Discussion
In addressing the WHO TPP for a syphilis confirmatory test, the
primary intended use of the TP-IgA POCT is an alternative to labora-
tory-based non-treponemal (RPR) testing, used in combination with
a syphilis total antibody (treponemal) screening test. Results of the
present studies show that the prototype TP-IgA POCT meets the
WHO TPP for a confirmatory POCT for active syphilis, with clinical
sensitivity and specificity greater than 95% and 80%, respectively. The
TP-IgA POCT can potentially be a useful diagnostic tool for confirma-
tion of active syphilis infections at the point-of-care in resource-con-
strained settings where both the availability of and access to
laboratory services are limited. In addition, it has the potential to sig-
nificantly reduce overtreatment by distinguishing active syphilis
from past/treated syphilis when used in conjunction with a trepone-
mal-specific total antibody test.
There are many rapid POCTs for syphilis total antibody already
available in the market, including the Alere DetermineTM and Vis-
itect devices examined here. These tests are highly sensitive, afford-
able and easy to use by healthcare workers in clinical settings with
minimal training [14,16,17]. Yet, because these tests are based on
detection of total treponemal-specific antibodies they cannot distin-
guish between active and past-treated infections. Use of these tests
without confirmatory testing for active syphilis is not only contrary
to policy in many countries, but introduces the risk of unnecessary
treatment of individuals who are treponemal antibody positive due
to previously treated syphilis, and non-treponemal test will be
required for subsequent clinical management [17]. This overtreat-
ment carries public health consequences as it may affect peoples’
willingness to use health services (e.g. antenatal care (ANC) for preg-
nant women) over fear of being administered unnecessary medica-
tions and stigmatisation [18,19]. Overtreatment could also lead to
drug stock-out in resource-constrained, high prevalence settings and
may contribute to the global shortage of Benzathine penicillin [20].uishing between active and past treated syphilis compared to stan-
od samples from pregnant/postpartum women in South Africa
A+/ RPR- TPHA-/RPR- TPHA-/RPR+ Total
ated syphilis No syphilis Biological false positive
3 2 10
484 0 493
487 2 503
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potential use of the TP-IgA POCT in field settings.
First, for the diagnosis of active syphilis with high RPR titre (8),
the use of TP-IgA POCT as a confirmatory test in combination with a
syphilis total antibody POCT could potentially deliver 96% to 100%
sensitivity. This level of sensitivity meets the WHO TPP and is similar
to that of other rapid POCTs for syphilis available on the market that
cannot discriminate past/treated from active syphilis [21]. Diagnosis
of active syphilis, however, could be challenging due to variation in
patient’s clinical manifestations and immune responses at different
stages of syphilis [22]. Subjects with a positive treponemal total anti-
body test but negative non-treponemal (or in this case TP-IgA) test
for syphilis could have past/treated syphilis, or in a small proportion
could have very early syphilis, long-standing latent syphilis or active
syphilis with negative non-treponemal test [23]. Those latter cases
could potentially be detected using a second but different treponemal
test, and those with two positive treponemal test results and no his-
tory of treated syphilis are candidates for treatment [11,24]. Although
clinics in resource-constrained settings may find this challenging, it
could still be worth doing given the risk and potential associated cost
of missing cases of untreated infection. Results from our study in
China indicated that six out of 153 active syphilis cases would have
been missed and three out of 151 “no syphilis” cases would have
been unnecessarily treated if only the TP-IgA POCT had been used.
However, if used together with other rapid tests the first six cases
would be deemed as requiring treatment and the later three cases
would be deemed biological false positives. We therefore suggest
that the TP-IgA POCT would be most suitable for use in combination
with a standard rapid treponemal total antibody test for diagnosis of
active syphilis infections in clinic settings. This would be an effective
and efficient testing algorithm in settings with limited laboratory
capacity. (Fig. 2)
Second, the diagnosis of syphilis infection with low RPR titre
(TPHA/TPPA +, RPR<8) would be of clinical interest. Although this
serological category is not included in the WHO TPP because RPR
remains stable at low titre in many cases of successfully treated syph-
ilis (serofast reaction), clinical guidelines in many countries dictate
that all patients reactive to both treponemal (TPHA or TPPA) and
non-treponemal tests (RPR) at any titre are considered to have activeFig. 2. Standard laboratory-based and proposed Point-of-care testing asyphilis and should be treated. Results of our South Africa study sug-
gested that the TP-IgA POCT could potentially be sensitive enough to
pick up syphilis cases with low RPR titre, enabling same day testing
and treatment at the point-of-care. In addition, the use of the TP-IgA
test in combination with another standard screening test would fur-
ther identify 71% of past-treated syphilis, significantly reducing over-
treatment. It is noted that the DPP Syphilis Screen & Confirm test,
although meeting theWHO TPP with a sensitivity of> 85% for detect-
ing samples with high RPR titre (8), does not appear to reduce over
treatment of syphilis [7,8].
Third, current treponemal serological tests for syphilis use native
or recombinant Treponema pallidum antigens to detect IgM and IgG
antibodies to treponemal components [25,26]. They are more sensi-
tive than non-treponemal tests for all stages of syphilis but cannot
distinguish active from past-treated infection and therefore, cannot
be used to monitor the effectiveness of syphilis treatment. Our study
findings showed that the TP-IgA POCT is highly sensitive, able to dis-
tinguish between active and past infections and can potentially be
used for monitoring treatment outcomes. It will also be of interest to
determine the persistence of IgA antibodies in patients with non-
venereal treponemal infections such as non-venereal trepanemato-
ses, which may confound results especially in young subjects from
endemic regions [8]. These particular applications of the TP-IgA
POCT, however, need to be further examined in prospective, longitu-
dinal field studies with a final manufactured version of the device.
Future studies should also evaluate diagnostic performance of the
test for congenital syphilis and in individuals who have become rein-
fected as people with repeated episodes of syphilis (e.g. key popula-
tion at high risk of STIs such as men who have sex with men) may
have different immunological responses compared to those with ini-
tial infection [27].
The present studies have some limitations. First, for the China
study we were unable to source the DPP tests to perform a head-to-
head comparison with the TP-IgA POCT in identifying active and/or
past/treated syphilis from a pool of pre-characterised stored plasma
samples as originally planned. This makes us unable to draw conclu-
sion on the potential advantage of the TP-IgA POCT compared to the
DPP test in distinguishing between active syphilis and past/treated
infections. Future study to directly compare the two tests for thislgorithms for diganosis of active syphilis among pregnant women.
M.D. Pham et al. / EClinicalMedicine 24 (2020) 100440 7purpose is needed. Second, for the South Africa study, there was a
low prevalence of active and/or past/treated syphilis among the study
population and no clinical data were collected so that the categorisa-
tion of syphilis status was solely based on serological tests, which
introduces some uncertainty and limits the generalisation of study
findings. Third, both studies were conducted in a laboratory environ-
ment with trained technical staff and using venous blood (either
fresh or plasma) rather than finger-prick samples that would be
more likely to be used in field settings. Therefore, future studies are
needed to examine diagnostic accuracy of the TP-IgA POCT, as per-
formed by health care worker in clinical settings, with different sam-
ple types.
In conclusion, our evaluation studies showed that the prototype
TP-IgA has met the WHO TPP performance criteria for a POCT for con-
firmatory diagnosis of active syphilis infections. The test demonstrated
its potential utility as an accurate confirmatory test when used in com-
bination with a treponemal total antibody-screening test. Further
study is warranted to assess diagnostic performance of the final manu-
factured test as well as its clinical utility in real world settings.Declaration of Competing Interest
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